Navigation Links
Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
Date:11/11/2008

New Data Presented at the Meeting Demonstrate Vitamin E May Help Prevent

Cardiovascular Events in Hp2-2 Diabetes

MONTVALE, N.J., Nov. 11 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) today announced new data demonstrating that discontinuation of Vitamin E in patients with the Hp2-2 Diabetes may result in an increased risk of heart attack and rapid deterioration of HDL function. These results were presented today at the Annual Scientific Sessions of the American Heart Association, underway in New Orleans.

"These data demonstrate that after detecting Hp2-2 Diabetes, physicians modified treatment and achieved improved outcomes for specific patients by prescribing vitamin E. These benefits were lost when treatment with vitamin E was abandoned," said Noah Berkowitz, M.D., President and CEO of Synvista Therapeutics. "These types of studies provide confirmation that our clinical laboratory test which determines haptoglobin genotype may be useful in selecting and guiding patient therapy. We believe that the use of our test will be an important facilitator of personalized medicine and will provide a standard by which physicians can influence clinical outcome."

About the Study

In a prospective study called ICARE, 2,241 individuals with diabetes mellitus age 55 or over from 47 primary-care clinics in Israel underwent haptoglobin genotype testing and were randomized to receive either Vitamin E or placebo. The subjects were then followed for three years to track heart attack (myocardial infarction or MI), stroke and death (cardiovascular and all cause). During the study, it was determined that those who had the Hp2-2 genotype and who also received vitamin E had a significantly lower incidence of MI
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
3. Synvista Therapeutics Posts Letter to Stockholders on Web Site
4. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
5. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
6. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
8. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
9. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
10. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
11. Synvista Therapeutics to be Featured on Wallst.net
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
(Date:12/17/2014)... --  Synageva BioPharma Corp. (NASDAQ: GEVA ... disorders, announced today its presentation at the upcoming J.P. ... Francisco, CA. Sanj K. ... on Monday, January 12, 2015, at 9:00 a.m. PST ... and may be accessed from the "Webcasts & Presentations" ...
(Date:12/15/2014)... , Dec. 15, 2014  Origin Agritech Limited (NASDAQ ... a technology-focused supplier of crop seeds in China ... for its fiscal year 2014 ended September 30, 2014, before ... The Company will host a teleconference on January 8, 2015, ... time to discuss the results. To participate in ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
... that a new market research report is available in its ... and companies http://www.reportlinker.com/p0203543/Gene-Therapy---technologies-markets-and-companies.html ... on gene therapy with 72 tables and 13 figures ... 700 selected references from the literature - Estimates ...
... Dec. 21, 2010 Exagen Diagnostics, Inc., a specialty ... today announced that it has been awarded $400,000 in ... program, which was created by Congress as part of ...  Proceeds from the grants will be used to advance ...
... Mass. and BRANFORD, Conn., Dec. 20, 2010 ... oncology-focused molecular diagnostics company, and HistoRx, Inc., ... to advance individualized patient care, today announced ... Metamark a worldwide license to the AQUA ...
Cached Biology Technology:Reportlinker Adds Gene Therapy - technologies, markets and companies 2Reportlinker Adds Gene Therapy - technologies, markets and companies 3Reportlinker Adds Gene Therapy - technologies, markets and companies 4Reportlinker Adds Gene Therapy - technologies, markets and companies 5Reportlinker Adds Gene Therapy - technologies, markets and companies 6Reportlinker Adds Gene Therapy - technologies, markets and companies 7Reportlinker Adds Gene Therapy - technologies, markets and companies 8Reportlinker Adds Gene Therapy - technologies, markets and companies 9Reportlinker Adds Gene Therapy - technologies, markets and companies 10Reportlinker Adds Gene Therapy - technologies, markets and companies 11Reportlinker Adds Gene Therapy - technologies, markets and companies 12Reportlinker Adds Gene Therapy - technologies, markets and companies 13Reportlinker Adds Gene Therapy - technologies, markets and companies 14Reportlinker Adds Gene Therapy - technologies, markets and companies 15Reportlinker Adds Gene Therapy - technologies, markets and companies 16Reportlinker Adds Gene Therapy - technologies, markets and companies 17Reportlinker Adds Gene Therapy - technologies, markets and companies 18Reportlinker Adds Gene Therapy - technologies, markets and companies 19Reportlinker Adds Gene Therapy - technologies, markets and companies 20Reportlinker Adds Gene Therapy - technologies, markets and companies 21Exagen Diagnostics Awarded $400,000 in Grants Under the QTDP Program 2Metamark and HistoRx Announce Licensing Agreement for AQUA® Technology 2
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... see the flowers of Edinburgh in full bloom in the depths ... the impact of global warming on spring flowering, published today in ... dating back to the late nineteenth century, has been used to ... further warming will have on plant life by the year 2080. ...
... faster than in any other location on Earth. Researchers at ... indicating that the changes are astonishingly fast. Many original species ... species from southern areas to migrate north, where they occupy ... renowned Science magazine will publish a joint article ...
... ANN ARBOR, Mich.---The growth of cancerous tumors is ... free radicals---highly reactive oxygen-containing molecules. It stands to ... antioxidants, which inhibit the rogue radicals, or with pro-oxidants, ... cancer cells to the point of vanquishing them. ...
Cached Biology News:Early spring time for Edinburgh? Study predicts effect of global warming on spring flowers 2The change in Arctic nature foreshadows the global environment of the future 2New method monitors early sign of oxidative stress in cancer 2